Last 12 months
Inside the activity.
0 purchase rows · 54 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2025 Filed May 9, 2025 23:43 UTC |
Bruls AnnetteCVP, EMEACLA
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 31,600 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004948 · doc4.xml · derivative · entry 2 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,600 Underlying: Common Stock · 31,600 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:43 UTC |
Bruls AnnetteCVP, EMEACLA
|
GrantCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004948 · doc4.xml · nonDerivative · entry 1 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,280 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Dahl Andrew M.SVP, Corporate Controller
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 5,670 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004946 · doc4.xml · derivative · entry 2 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,670 Underlying: Common Stock · 5,670 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Dahl Andrew M.SVP, Corporate Controller
|
GrantCommon Stock | 3,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004946 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,106.5266 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Markowitz WayneGM & SVP, Surgical
|
GrantPerformance Rights · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004945 · doc4.xml · derivative · entry 5 Markowitz Wayne · CIK 0001991414 · GM & SVP, Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Markowitz WayneGM & SVP, Surgical
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 17,100 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004945 · doc4.xml · derivative · entry 4 Markowitz Wayne · CIK 0001991414 · GM & SVP, Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,100 Underlying: Common Stock · 17,100 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Markowitz WayneGM & SVP, Surgical
|
GrantCommon Stock | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004945 · doc4.xml · nonDerivative · entry 3 Markowitz Wayne · CIK 0001991414 · GM & SVP, Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,349.1916 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Chopra DaveenCVP, TMTT
|
GrantPerformance Rights · Derivative | 9,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004944 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Chopra DaveenCVP, TMTT
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 47,000 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004944 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Chopra DaveenCVP, TMTT
|
GrantCommon Stock | 9,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004944 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,576 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
GrantPerformance Rights · Derivative | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004942 · doc4.xml · derivative · entry 7 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,400 Underlying: Common Stock · 13,400 shares Expires not disclosed F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 75,200 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004942 · doc4.xml · derivative · entry 6 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,200 Underlying: Common Stock · 75,200 shares Expires 2032-05-07 F4 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
GrantCommon Stock | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004942 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,098 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Wood Larry LGlobal President TAVR & Surg
|
GrantPerformance Rights · Derivative | 11,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004940 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,050 Underlying: Common Stock · 11,050 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Wood Larry LGlobal President TAVR & Surg
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 62,000 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004940 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Wood Larry LGlobal President TAVR & Surg
|
GrantCommon Stock | 11,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004940 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,888.3913 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Zovighian Bernard JDirector · CEO
|
GrantPerformance Rights · Derivative | 43,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · derivative · entry 7 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,550 Underlying: Common Stock · 43,550 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Zovighian Bernard JDirector · CEO
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 244,400 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · derivative · entry 6 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,400 Underlying: Common Stock · 244,400 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 4,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · nonDerivative · entry 4 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 17,076 Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 4,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,422.5511 Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC |
Zovighian Bernard JDirector · CEO
|
GrantCommon Stock | 43,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,544.5511 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:33 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantPerformance Rights · Derivative | 8,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004939 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,375 Underlying: Common Stock · 8,375 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:33 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 47,000 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004939 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:33 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantCommon Stock | 8,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004939 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,742.3707 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2025 Filed May 9, 2025 23:34 UTC |
Markowitz WayneGM & SVP, Surgical
|
Tax withholdingCommon Stock | 300 | $74.92 | $22,476.00 |
DisclosureSEC source: 0001225208-25-004945 · doc4.xml · nonDerivative · entry 2 Markowitz Wayne · CIK 0001991414 · GM & SVP, Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,999.1916 Read SEC document |
| May 07, 2025 Filed May 9, 2025 23:34 UTC |
Markowitz WayneGM & SVP, Surgical
|
SaleCommon Stock | 268 | $75.08 | $20,120.85 |
DisclosureSEC source: 0001225208-25-004945 · doc4.xml · nonDerivative · entry 1 Markowitz Wayne · CIK 0001991414 · GM & SVP, Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,299.1916 Read SEC document |
| May 07, 2025 Filed May 9, 2025 23:34 UTC |
Chopra DaveenCVP, TMTT
|
Tax withholdingCommon Stock | 627 | $74.92 | $46,974.84 |
DisclosureSEC source: 0001225208-25-004944 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,376 Read SEC document |
| May 07, 2025 Filed May 9, 2025 23:34 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 1,406 | $74.92 | $105,337.52 |
DisclosureSEC source: 0001225208-25-004942 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,698 Read SEC document |
| May 07, 2025 Filed May 9, 2025 23:34 UTC |
Wood Larry LGlobal President TAVR & Surg
|
Tax withholdingCommon Stock | 819 | $74.92 | $61,359.48 |
DisclosureSEC source: 0001225208-25-004940 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,838.3913 Read SEC document |
| May 07, 2025 Filed May 9, 2025 23:34 UTC |
Zovighian Bernard JDirector · CEO
|
Tax withholdingCommon Stock | 4,253 | $74.92 | $318,634.76 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,994.5511 Read SEC document |
| May 07, 2025 Filed May 9, 2025 23:33 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 851 | $74.92 | $63,756.92 |
DisclosureSEC source: 0001225208-25-004939 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,367.3707 Read SEC document |
| May 06, 2025 Filed May 6, 2025 21:13 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 1,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 8 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 12,954 Read SEC document |
| May 06, 2025 Filed May 6, 2025 21:13 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 1,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 6 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,247.5511 Read SEC document |
| May 05, 2025 Filed May 6, 2025 21:13 UTC |
Zovighian Bernard JDirector · CEO
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,462 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-25-004799 · doc4.xml · derivative · entry 10 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,462 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one yearafter the grant date in four equal annual installments. Read SEC document |
| May 05, 2025 Filed May 6, 2025 21:13 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 1,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 7 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 11,918 Read SEC document |
| May 05, 2025 Filed May 6, 2025 21:13 UTC |
Zovighian Bernard JDirector · CEO
|
SaleCommon Stock | 5,980 | $74.91 | $447,976.75 |
DisclosureSEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 5 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,283.5511 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.67 to $75.15 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2025 Filed May 6, 2025 21:13 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 1,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 4 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,263.5511 Read SEC document |
| May 05, 2025 Filed May 6, 2025 21:13 UTC |
Zovighian Bernard JDirector · CEO
|
Exercise / conversionCommon Stock | 7,462 | $45.28 | $337,854.74 |
DisclosureSEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,745.5511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024. Read SEC document |
| May 04, 2025 Filed May 5, 2025 23:30 UTC |
Lippis Daniel J.CVP, JAPAC
|
Tax withholdingCommon Stock | 247 | $75.65 | $18,685.55 |
DisclosureSEC source: 0001225208-25-004769 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,391.1066 Read SEC document |
| May 04, 2025 Filed May 5, 2025 23:29 UTC |
Chopra DaveenCVP, TMTT
|
Tax withholdingCommon Stock | 289 | $75.65 | $21,862.85 |
DisclosureSEC source: 0001225208-25-004767 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,003 Read SEC document |
| May 04, 2025 Filed May 5, 2025 23:29 UTC |
Wood Larry LGlobal President TAVR & Surg
|
Tax withholdingCommon Stock | 410 | $75.65 | $31,016.50 |
DisclosureSEC source: 0001225208-25-004768 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,657.3913 Read SEC document |
| May 04, 2025 Filed May 5, 2025 23:29 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 508 | $75.65 | $38,430.20 |
DisclosureSEC source: 0001225208-25-004766 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,218.3707 Read SEC document |
| May 04, 2025 Filed May 5, 2025 23:28 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 648 | $75.65 | $49,021.20 |
DisclosureSEC source: 0001225208-25-004765 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,104 Read SEC document |
| May 04, 2025 Filed May 6, 2025 21:13 UTC |
Zovighian Bernard JDirector · CEO
|
Tax withholdingCommon Stock | 543 | $75.65 | $41,077.95 |
DisclosureSEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,283.5511 Read SEC document |
| May 03, 2025 Filed May 5, 2025 23:30 UTC |
Lippis Daniel J.CVP, JAPAC
|
Tax withholdingCommon Stock | 225 | $75.65 | $17,021.25 |
DisclosureSEC source: 0001225208-25-004769 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,638.1066 Read SEC document |
| May 03, 2025 Filed May 5, 2025 23:29 UTC |
Chopra DaveenCVP, TMTT
|
Tax withholdingCommon Stock | 291 | $75.65 | $22,014.15 |
DisclosureSEC source: 0001225208-25-004767 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,292 Read SEC document |
| May 03, 2025 Filed May 5, 2025 23:29 UTC |
Wood Larry LGlobal President TAVR & Surg
|
Tax withholdingCommon Stock | 396 | $75.65 | $29,957.40 |
DisclosureSEC source: 0001225208-25-004768 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,067.3913 Read SEC document |
| May 03, 2025 Filed May 5, 2025 23:29 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 480 | $75.65 | $36,312.00 |
DisclosureSEC source: 0001225208-25-004766 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,726.3707 Read SEC document |
| May 03, 2025 Filed May 5, 2025 23:28 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 635 | $75.65 | $48,037.75 |
DisclosureSEC source: 0001225208-25-004765 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,752 Read SEC document |
| May 03, 2025 Filed May 6, 2025 21:13 UTC |
Zovighian Bernard JDirector · CEO
|
Tax withholdingCommon Stock | 527 | $75.65 | $39,867.55 |
DisclosureSEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,826.5511 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.